AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF LNP023 IN SUBJECTS WITH C3 GLOMERULOPATHY: INTERIM ANALYSIS OF PHASE 2 STUDY

  Back
WCN23-0403
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Other CKD
 
 
 
 
AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF LNP023 IN SUBJECTS WITH C3 GLOMERULOPATHY: INTERIM ANALYSIS OF PHASE 2 STUDY
M. Nester, C.(1);Eisenberger, U.(2);Karras, A.(3);Le Quintrec-Donnette, M.(4);Lightstone, L.(5,6)*;Praga, M.(7);Remuzzi, G.(8);Jose Soler, M.(9);Liu, J.(10);Meier, M.(11);Tawfik, R.(12);Junge, G.(13);Biondani, A.(13);J Trapani, A.(14);Webb, N.(11);K Wong, E.(15,16);
ie: Azwin Z.1, Siti Y.1, John D.2
(1)University Of Iowa Molecular Otolaryngology And Renal Research Laboratories, Renal Division, Iowa City, United States;(2)University Hospital Essen- University Of Duisburg-Essen, Department Of Nephrology, Essen, Germany;(3)Hopital Europeen Georges Pompidou, Nephrology Department, Paris, France;(4)Service De Néphrologie Et Transplantation Rénale- Centre Hospitalier Universitaire De Montpellier, Department Of Nephrology And Transplantation, Montpellier, France;(5)Imperial College London- Centre For Inflammatory Disease, Department Of Immunology And Inflammation, London, United Kingdom;(6)Imperial College Healthcare Nhs Trust- Hammersmith Hospital, Imperial College Renal And Transplant Centre, London, United Kingdom;(7)Complutense University- Hospital Universitario 12 De Octubre, Department Of Medicine, Madrid, Spain;(8)Istituto Di Ricerche Farmacologiche Mario Negri, Department Of Immunology And Clinical Transplantation And Department Of Medicine, Bergamo, Italy;(9)Hospital Universitari Vall D’Hebron, Department Of Nephrology, Barcelona- Catalunya, Spain;(10)Novartis Pharmaceuticals Corporation, Biostatistics Crm, East Hanover- New Jersey, United States;(11)Novartis Pharma Ag, Global Drug Development, Basel- Basel-Stadt, Switzerland;(12)Novartis Pharmaceuticals Corporation, Global Development Organization, East Hanover- New Jersey, United States;(13)Novartis Institutes For Biomedical Research, Department Of Translational Medicine, Basel- Basel-Stadt, Switzerland;(14)Novartis Pharmaceuticals Corporation, Clinical Development, East Hanover- New Jersey, United States;(15)Newcastle University, Department Of Nephrology, Newcastle Upon Tyne, United Kingdom;(16)National Renal Complement Therapeutics Centre- Royal Victoria Infirmary, Department Of Nephrology, Newcastle Upon Tyne, United Kingdom;
https://storage.unitedwebnetwork.com/files/1041/13bc27fbf64f1570498838327073a918.pdf
 
if any